A reduction in HIV positive and an increase in hepatitis C positive subjects in methadone maintenance treatments

Dieter Ladewig
Psychiatrische Universitätsklinik Basel, Switzerland

Methadone maintenance treatment (MMT) has been available in Switzerland for more than 20 years. The prescription of methadone is part of a comprehensive policy aimed at reducing illicit opiate use, HIV risk behaviour and crime rates [3].

Although this practice is well established some still doubt the efficiency of MMT. In the canton of Basel City the use of methadone substitution in the treatment of opiate dependence is evaluated yearly [1, 2].

This study presents the results of a cross-sectional survey (n = 1013) carried out in 2000. Patients were interviewed by their general practitioners and 89% of the questionnaires returned. The results presented pertain to this responder sample (n = 896).

Results

The majority of the patient population underwent HIV testing. In 2000, 9.4% of the sample was HIV positive. In 1992 the corresponding figure was 29%. The proportion of respondents with an unknown HIV status was 26.5% in 1995 and had fallen to 0.6% in 1999 (Table 1). These improvements indicate that substitution treatment and the offer of needle exchanges effective.

Whilst the results for HIV status are positive, the reports on hepatitis status remain alarming. Overall 63.5% of the population tested positive for hepatitis C (Table 2). The proportion of non-tested persons or those who failed to answer is high in this group at 27% respectively 13%.

In conclusion this aspect of drug taking behaviour induced sequela needs to be examined more closely.

References

1 Petitjean S, Bucheli B, Kuntze M, Ladewig D. Resultate aus der Begleitevaluation der Methadonbehandlungen im Kanton Basel-Stadt Nr. 5; Dezember 2000.

Table 1
HIV prevalence between 1992 and 2000 in patients in MMT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV n = 501</td>
<td>29.0</td>
<td>12.5</td>
<td>10.8</td>
<td>11.5</td>
<td>9.4</td>
</tr>
<tr>
<td>HIV positive (%)</td>
<td>34.0</td>
<td>61.0</td>
<td>75.8</td>
<td>84.6</td>
<td>90.0</td>
</tr>
<tr>
<td>Unknown HIV state</td>
<td>37.0</td>
<td>26.5</td>
<td>13.4</td>
<td>3.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
</tbody>
</table>

Table 2
Hepatitis A, B, and C seroprevalence in patients in MMT

<table>
<thead>
<tr>
<th>Hepatitis (n = 700*)</th>
<th>A</th>
<th>B</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>negative (%)</td>
<td>45.7</td>
<td>34.4</td>
<td>36.5</td>
</tr>
<tr>
<td>positive (%)</td>
<td>–</td>
<td>3.9</td>
<td>55.5</td>
</tr>
<tr>
<td>positive vaccinated (%)</td>
<td>33.6</td>
<td>36.9</td>
<td>–</td>
</tr>
<tr>
<td>known positive (%)</td>
<td>20.7</td>
<td>24.8</td>
<td>8.0</td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
</tr>
</tbody>
</table>

* Results from the responder sample (700 of 896 patients); overall 13% were not tested for hepatitis A, B and C; and 33% had an unknown hepatitis A state, 25% an unknown hepatitis B state, and 27% an unknown hepatitis C state.
The many reasons why you should choose SMW to publish your research

**What Swiss Medical Weekly has to offer:**

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

**Editorial Board**

Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich (Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

**International Advisory Committee**

Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

**Guidelines for authors:**

http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch